If 853 doesn't make it past either pivotal trial in the next 2 years, they could sell the company, or partner / sell their lead drug.
In the latter scenario, they could use the proceeds to develop their other assets, and there's also the option of restarting R&D and continuing the licensing mill. Repriming the pipeline will be hard to do without a lot of money and the credibility of an in-house success, and I'd favor either a full sale or continued development of existing assets.
I do think they have enough promising irons in the fire in their lead candidates and legacy platform deals that it's pretty likely at least one will succeed.